Rivaroxaban in Rheumatic Heart Disease–Associated Atrial Fibrillation

The study compared the efficacy and safety of rivaroxaban versus vitamin K antagonist therapy in patients with rheumatic heart disease-associated atrial fibrillation. A total of 4,565 patients were enrolled, with 4,531 included in the final analysis. The primary efficacy outcome was a composite of stroke, systemic embolism, myocardial infarction, or death from vascular or unknown causes. Results showed that vitamin K antagonist therapy was superior to rivaroxaban, with a lower rate of cardiovascular events and death, without an increased risk of bleeding.

The study compared the efficacy and safety of rivaroxaban versus vitamin K antagonist therapy in patients with rheumatic heart disease-associated atrial fibrillation. A total of 4,565 patients were enrolled, with 4,531 included in the final analysis. The primary efficacy outcome was a composite of stroke, systemic embolism, myocardial infarction, or death from vascular or unknown causes. Results showed that vitamin K antagonist therapy was superior to rivaroxaban, with a lower rate of cardiovascular events and death, without an increased risk of bleeding.